HAO Haoxi Health Technology Ltd
Price Chart
Executive Summary
Haoxi Health Technology (HAO) is soliciting shareholder approval for a massive authorized share capital increase (from $384M to $35.2T), a reverse stock split of up to 1-for-8,000, and related charter amendments at a June 2, 2026 EGM. The reverse split is explicitly intended to regain compliance with Nasdaq's $1.00 minimum bid price rule, as the stock trades near $0.045. This filing follows a dilutive $6M offering 9 days prior and comes amid a going-concern qualification from the auditor and declining revenue ($32.8M in FY2025 vs $48.5M in FY2024).
Actionable Insight
This is a last-ditch effort to avoid delisting from a sub-$0.10 stock with a going-concern warning. The reverse split authorization (up to 1-for-8,000) is extreme and signals the stock is at imminent risk of Nasdaq delisting. The massive authorized share increase gives the board unlimited capacity to issue shares, likely for further dilutive financings. Traders should expect continued dilution and potential delisting — avoid long positions and consider shorting into any pre-EGM pump.
Key Facts
- EGM on June 2, 2026 to vote on increasing authorized share capital from $384,250,000 to $35,200,000,000,000 (100 trillion Class A + 10 trillion Class B shares).
- Board authorized to implement a reverse stock split of up to 1-for-8,000 within 2 years to meet Nasdaq's $1.00 minimum bid price rule.
- Stock closed at $0.045 on May 11, 2026 — well below the $1.00 minimum and the $0.10 Low Priced Stocks Rule threshold.
- On the Record Date (May 21, 2026), only 1,904,604 Class A and 317,897 Class B shares were outstanding.
- This filing follows a dilutive $6M offering (9M shares + 177M pre-funded warrants) filed May 12, 2026.
- Auditor issued a going-concern qualification; FY2025 revenue declined to $32.8M from $48.5M in FY2024.
Financial Impact
Massive authorized share increase (91,600x current) enables unlimited future dilution. Reverse split up to 1-for-8,000 is a distress signal, not a value event. Combined with the prior $6M offering, potential fully diluted share count could exceed 243M vs 58.8M pre-offering.
Risk Factors
- Nasdaq delisting if reverse split fails or is insufficient to maintain $1.00 bid price for 10 consecutive days.
- Massive dilution from authorized share increase enables further capital raises at distressed prices.
- Going-concern qualification from auditor indicates potential business failure risk.
- China regulatory risks and declining revenue fundamentals.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060088 |
| Document: ea0291734-01.htm | 0001213900-26-060088 |
| Document: ea029173401ex99-2.htm | 0001213900-26-060088 |
| Document: 0001213900-26-060088-index-headers.html | 0001213900-26-060088 |
| Document: 0001213900-26-060088-index.html | 0001213900-26-060088 |
| Document: 0001213900-26-060088.txt | 0001213900-26-060088 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
28d ago
|
6-K
| $1.34 $1.21 | ▲ +9.70% | ▲ +11.38% | $1.08 (+19.40%) |
|
May 19, 2026
4w ago
|
Press Release
| $1.79 $0.8603 | ▲ +51.99% | ▲ +54.24% | $1.08 (+39.73%) |
|
May 12, 2026
5w ago
|
424B5
| $5.21 $1.79 | ▲ +65.60% | ▲ +65.00% | $1.08 (+79.27%) |
|
Mar 3, 2026
15w ago
|
Press Release
| $142.08 $148.48 | ▲ +4.50% | ▲ +4.98% | $1.08 (−99.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access